- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02614196
Evaluering af effektivitet og sikkerhed af Galcanezumab til forebyggelse af episodisk migræne - EVOLVE-2-undersøgelsen (EVOLVE-2)
En fase 3, randomiseret, dobbeltblind, placebokontrolleret undersøgelse af LY2951742 i patienter med episodisk migræne - EVOLVE-2 undersøgelsen
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Ciudad Autonoma de Buenos Aire, Argentina, C1012AAR
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Ciudad Autonoma de Buenos Aire, Argentina, C1013AAB
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Ciudad Autonoma de Buenos Aire, Argentina, C1128AAF
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Ciudad Autonoma de Buenos Aires, Argentina, C1046AAQ
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Glasgow, Det Forenede Kongerige, G51 4TF
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hull, Det Forenede Kongerige, HU3 2JZ
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Liverpool, Det Forenede Kongerige, L9 7LJ
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
London, Det Forenede Kongerige, SE5 9RS
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Stoke-on-Trent, Det Forenede Kongerige, ST4 6QG
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85023
- Arizona Research Center
-
Phoenix, Arizona, Forenede Stater, 85004
- 21st Century Neurology
-
-
California
-
Apple Valley, California, Forenede Stater, 92307
- Axiom Research
-
Los Angeles, California, Forenede Stater, 90048
- Cedars Sinai Medical Center
-
Montclair, California, Forenede Stater, 91763
- Catalina Research Institute, LLC
-
Oakland, California, Forenede Stater, 94607
- Pacific Research Partners, LLC
-
San Diego, California, Forenede Stater, 92108
- Medical Center for Clinical Research
-
San Francisco, California, Forenede Stater, 94102
- Optimus Medical Group
-
Sherman Oaks, California, Forenede Stater, 91403
- Schuster Medical Research Institute
-
-
Colorado
-
Centennial, Colorado, Forenede Stater, 80112
- IMMUNOe International Research Centers
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33134
- Clinical Research of South Florida
-
Hollywood, Florida, Forenede Stater, 33021
- Sunrise Clinical Research
-
Jacksonville, Florida, Forenede Stater, 32205
- Westside Center for Clinical Research
-
Jacksonville, Florida, Forenede Stater, 32256
- Clinical NeuroScience Solutions Inc
-
Ocoee, Florida, Forenede Stater, 34761
- Sensible Healthcare
-
Tampa, Florida, Forenede Stater, 33634
- Meridien Research
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30331
- Atlanta Center of Medical Research
-
-
Illinois
-
Champaign, Illinois, Forenede Stater, 61820
- Christie Clinic, LLC
-
Chicago, Illinois, Forenede Stater, 60642
- Diamond Headache Clinic
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46256
- Josephson Wallack Munshower Neurology
-
-
Kansas
-
Wichita, Kansas, Forenede Stater, 67205
- Heartland Research Associates
-
-
Massachusetts
-
New Bedford, Massachusetts, Forenede Stater, 02740
- Novex Clinical Research
-
-
Michigan
-
Farmington Hills, Michigan, Forenede Stater, 48334
- Quest Research Institute
-
-
Missouri
-
Hazelwood, Missouri, Forenede Stater, 63042
- Healthcare Research Network - Hazelwood
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89113
- Nevada Headache Institute
-
-
New Jersey
-
Toms River, New Jersey, Forenede Stater, 08755
- Bio Behavioral Health
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87102
- Albuquerque Clinical Trials
-
-
New York
-
Binghamton, New York, Forenede Stater, 13760
- Regional Clinical Research
-
Brooklyn, New York, Forenede Stater, 11235
- SPRI Clinical Trials, LLC.
-
-
North Carolina
-
High Point, North Carolina, Forenede Stater, 27265
- High Point Clinical Trials Center
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44320
- Neurology & Neuroscience Associates, Inc.
-
Cincinnati, Ohio, Forenede Stater, 45219
- Univ of Cincinnati College of Medicine
-
Columbus, Ohio, Forenede Stater, 43214
- Urgent Care Specialists, LLC
-
Dayton, Ohio, Forenede Stater, 45424
- Urgent Care Specialists, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73103
- IPS Research Company
-
-
Oregon
-
Springfield, Oregon, Forenede Stater, 97477
- Oregon Neurology Associates
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19114
- Clinical Research of Philadelphia
-
-
South Carolina
-
Greer, South Carolina, Forenede Stater, 29651
- Mountain View Clinical Research, Inc
-
Mount Pleasant, South Carolina, Forenede Stater, 29464
- Coastal Carolina Research Center, Inc.
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- FutureSearch Trials
-
Houston, Texas, Forenede Stater, 77074
- Clinical Trial Network
-
Waxahachie, Texas, Forenede Stater, 75165
- Clinpoint Trial, LLC
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84109
- Foothill Family Clinic
-
South Jordan, Utah, Forenede Stater, 84095
- Jordan River Family Medicine
-
-
Virginia
-
Newport News, Virginia, Forenede Stater, 23606
- Health Research of Hampton Roads Inc
-
Virginia Beach, Virginia, Forenede Stater, 23456
- Sentara Neurology Specialists
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98007-4209
- Northwest Clinical Research Center
-
Seattle, Washington, Forenede Stater, 98104
- Polyclinic
-
-
Wisconsin
-
Middleton, Wisconsin, Forenede Stater, 53562
- Dean Foundation for Health Research and Education
-
-
-
-
-
Amsterdam, Holland, 1078 VV
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Geleen, Holland, 6162 BG
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Leiden, Holland, 2333 ZA
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nijmegen, Holland, 6532 SZ
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tilburg, Holland, 5042 AD
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Zwolle, Holland, 8025 AB
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Hadera, Israel, 38100
- Hillel Yaffe
-
Haifa, Israel, 3525408
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kfar Saba, Israel, 4420122
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Ramat Gan, Israel, 5266202
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Hwaseong-si, Korea, Republikken, 18450
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Seoul, Korea, Republikken, 03080
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Seoul, Korea, Republikken, 01830
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Seoul, Korea, Republikken, 03181
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Seoul, Korea, Republikken, 06351
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
Seoul, Korea, Republikken, 07441
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Seoul, Korea, Republikken, 08308
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
-
-
-
-
-
Aguascalientes, Mexico, 20217
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Culiacan, Mexico, 80020
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Merida, Mexico, 97070
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mexico City, Mexico, 03740
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
México City, Mexico, 03310
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Las Piedras, Puerto Rico, 00771
- Cortex, PSC
-
San Juan, Puerto Rico, 00918
- SomniCare Sleep Institute
-
-
-
-
-
Barcelona, Spanien, 08035
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Barcelona, Spanien, 08907
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Elda, Spanien, 03600
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Santander, Spanien, 39008
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Valencia, Spanien, 46010
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Valencia, Spanien, 46026
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Valladolid, Spanien, 47005
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Kaohsiung, Taiwan, 80756
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taichung, Taiwan, 43761
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tainan, Taiwan, 70142
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tainan, Taiwan, 71004
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taipei, Taiwan, 11217
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Taipei, Taiwan, 220
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Brno, Tjekkiet, 656 91
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kladno, Tjekkiet, 27201
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Praha 10, Tjekkiet, 100 00
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Praha 2, Tjekkiet, 120 00
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Praha 6, Tjekkiet, 160 00
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Praha 8, Tjekkiet, 182 00
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Berlin, Tyskland, 10117
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bielefeld, Tyskland, 33647
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bochum, Tyskland, 44787
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bochum, Tyskland, 44797
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Essen, Tyskland, 45147
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Halle, Tyskland, 06120
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hamburg, Tyskland, 20246
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Jena, Tyskland, 07747
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kassel, Tyskland, 34121
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Königstein, Tyskland, 61462
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Prien, Tyskland, 83209
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tübingen, Tyskland, 72076
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inklusionskriterier:
- Har en diagnose af migræne som defineret af International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 betaversion (1.1 eller 1.2) (ICHD-3 2013), med en historie med migrænehovedpine på mindst 1 år før til screening, debut af migræne før 50 år og MÅNEDLIG frekvens på 4-14 MHD.
Ekskluderingskriterier:
- Er i øjeblikket tilmeldt eller har deltaget inden for de sidste 30 dage eller inden for 5 halveringstider (alt efter hvad der er længst) i et klinisk forsøg, der involverer et forsøgsprodukt.
- Nuværende brug eller tidligere eksponering for galcanezumab eller et andet Calcitonin Gen-Relateret Peptid (CGRP) antistof.
- Kendt overfølsomhed over for flere lægemidler, monoklonale antistoffer eller andre terapeutiske proteiner eller over for galcanezumab.
- Anamnese med vedvarende daglig hovedpine, klyngehovedpine eller migræne-subtyper inklusive hemiplegisk (sporadisk eller familiær) migræne, oftalmoplegisk migræne og migræne med hjernestamme-aura (basilar-type migræne) defineret af IHS ICHD-3 beta.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Galcanezumab 120mg
Galcanezumab 240 mg givet som startdosis ved første dosisbesøg efterfulgt af galcanezumab 120 mg én gang om måneden i 5 måneder ved subkutan (SC) injektion.
|
Administreret SC
Andre navne:
|
Eksperimentel: Galcanezumab 240mg
Galcanezumab 240 mg givet ved subkutan injektion én gang om måneden i 6 måneder.
|
Administreret SC
Andre navne:
|
Placebo komparator: Placebo
Placebo givet ved SC-injektion én gang om måneden i 6 måneder.
|
Administreret SC
|
Eksperimentel: Galcanezumab 120mg maksimal udvidet tilmeldingskohorte
Galcanezumab 240 mg givet som startdosis ved første dosisbesøg efterfulgt af galcanezumab 120 mg én gang om måneden i 5 måneder ved subkutan (SC) injektion.
|
Administreret SC
Andre navne:
|
Eksperimentel: Galcanezumab 240mg maksimal udvidet tilmeldingskohorte
Galcanezumab 240 mg givet ved subkutan injektion én gang om måneden i 6 måneder.
|
Administreret SC
Andre navne:
|
Placebo komparator: Placebo maksimal udvidet tilmeldingskohorte
Placebo givet ved SC-injektion én gang om måneden i 6 måneder.
|
Administreret SC
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Samlet gennemsnitlig ændring fra baseline i antallet af månedlige dage med migrænehovedpine
Tidsramme: Baseline, måned 1 til og med måned 6
|
Migrænehovedpinedag (MHD): En kalenderdag, hvor der opstod migrænehovedpine eller sandsynlig migrænehovedpine. Migrænehovedpine: En hovedpine, med eller uden aura, af ≥30 minutters varighed med begge følgende påkrævede træk (A og B): A) Mindst 2 af følgende hovedpinekarakteristika: Ensidig lokalisering; Pulserende kvalitet; Moderat eller svær smerteintensitet; Forværring ved eller forårsagelse af undgåelse af rutinemæssig fysisk aktivitet; OG B) Under hovedpine mindst én af følgende: Kvalme og/eller opkastning; Fotofobi og fonofobi; Samlet gennemsnit er afledt af gennemsnittet af måned 1 til 6 fra mixed model repeated measurements (MMRM) model. Least Square (LS)-middelværdi blev beregnet ved hjælp af mixed model repeated measurements (MMRM) model med behandling, poolet land, måned og behandling efter måned, baseline og baseline for måned som faste effekter. |
Baseline, måned 1 til og med måned 6
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Gennemsnitlig procentdel af deltagere med reduktion fra baseline ≥50 %, ≥75 % og 100 % i månedlige migrænehovedpinedage
Tidsramme: Baseline, måned 1 til og med måned 6
|
Migrænehovedpinedag (MHD): En kalenderdag, hvor der opstod migrænehovedpine eller sandsynlig migrænehovedpine. Middel er afledt af gennemsnittet af måneder 1 til 6 fra generaliserede lineære blandede modeller gentagne mål. Gennemsnitlige procentdel af deltagere blev beregnet med en generaliseret lineær blandet model gentaget måling metode med behandling, måned og behandling for måned, baseline. |
Baseline, måned 1 til og med måned 6
|
Gennemsnitlig ændring fra baseline i det migrænespecifikke livskvalitetsspørgeskema (MSQ) Version 2.1 Rollefunktionsbegrænsende domæne
Tidsramme: Baseline, måned 4 til og med måned 6
|
MSQ v2.1 blev udviklet til at imødegå fysiske og følelsesmæssige begrænsninger af særlig interesse for personer med migræne. Den består af 14 elementer, der adresserer 3 domæner:(1) Rolle Funktionsbegrænsende (punkt 1-7);(2) Rollefunktion- Forebyggende (punkt 8-11);&(3) Følelsesmæssig funktion (punkt 12-14) .Svarmuligheder spænder fra "ingen af tiden" (værdi 1) til "hele tiden" (værdi 6), og omkodes omvendt (værdi 6 til 1), før domæneresultaterne beregnes. Samlede råscores for hver domæne er summen af den endelige vareværdi for alle varer i det pågældende domæne. Efter at den samlede råscore er beregnet for hvert domæne, transformeres de til en 0-100 skala med højere score, der indikerer en bedre sundhedsstatus og en positiv ændring i score, der afspejler funktionel forbedring. Middel er afledt af gennemsnittet af måneder 4 til 6 fra MMRM-modellen. LSMean blev beregnet ved hjælp af MMRM-model med behandling, samlet land, måned, behandling efter måned, baseline for måned & baseline MHD-kategori som faste faktorer. |
Baseline, måned 4 til og med måned 6
|
Samlet gennemsnitlig ændring fra baseline i antallet af månedlige dage med migrænehovedpine, der kræver medicin til akut behandling af migræne eller hovedpine
Tidsramme: Baseline, måned 1 til og med måned 6
|
Migrænehovedpinedag (MHD): En kalenderdag, hvor der opstod migrænehovedpine eller sandsynlig migrænehovedpine. Samlet gennemsnit er afledt af gennemsnittet af måned 1 til 6 fra MMRM-modellen.LSMean blev beregnet ved hjælp af MMRM-model med behandling, poolet land, måned, behandling for måned, baseline, baseline for måned og baseline MHD-kategori som faste effekter. |
Baseline, måned 1 til og med måned 6
|
Gennemsnitlig ændring fra baseline i Patient Global Impression of Severity (PGI-S) vurdering
Tidsramme: Baseline, måned 4 til og med måned 6
|
PGI-S-skalaen er et deltagerbedømt instrument, der måler patienters eget globale indtryk af deres sygdoms sværhedsgrad.
Deltageren blev instrueret som følger: "I betragtning af migræne som en kronisk tilstand, hvordan ville du vurdere dit sygdomsniveau?" Svarmulighederne var fra 1 ("normal, slet ikke syg") til 7 ("ekstremt syg").
Middel er afledt af gennemsnittet af måneder 4 til 6 fra MMRM-modellen.
LSMean blev beregnet ved hjælp af MMRM-model med behandling, samlet land, måned, behandling efter måned, baseline, baseline for måned og baseline MHD-kategori som faste faktorer.
|
Baseline, måned 4 til og med måned 6
|
Samlet gennemsnitlig ændring fra baseline i hovedpinetimer
Tidsramme: Baseline, måned 1 til og med måned 6
|
Hovedpinetimer beregnes som det samlede antal hovedpinetimer, hvor hovedpine opstod.
Samlet gennemsnit er afledt af gennemsnittet af måned 1 til 6 fra MMRM-modellen.
LSMean blev beregnet ved hjælp af MMRM-model med behandling, samlet land, måned, behandling efter måned, baseline, baseline for måned og baseline MHD-kategori.
|
Baseline, måned 1 til og med måned 6
|
Gennemsnitlig ændring fra baseline i den samlede score for migræne handicapvurdering (MIDAS).
Tidsramme: Baseline, måned 6
|
MIDAS er en deltagerbedømt skala, som er designet til at kvantificere hovedpinerelateret handicap over en 3-måneders periode. Dette instrument består af fem punkter, der afspejler antallet af dage, der er rapporteret som manglende eller med nedsat produktivitet på arbejde eller hjemme, og antallet af dage med mistede sociale begivenheder. Hver vare har et numerisk svarområde fra 0 til 90 dage, hvis dage udebliver fra arbejde eller hjemme, tælles de ikke som dage med nedsat produktivitet på arbejde eller hjemme. De numeriske svar summeres til at give en samlet score fra 0 til 270, hvor en højere værdi indikerer mere handicap. LSMean blev beregnet ved hjælp af MMRM-model med behandling, samlet land, måned, behandling efter måned, baseline, baseline for måned og baseline MHD-kategori som faste faktorer. |
Baseline, måned 6
|
Procentdel af deltagere, der udvikler antistof-antistoffer (ADA) mod Galcanezumab
Tidsramme: Måned 1 til og med måned 6
|
Behandling emergent (TE) ADA-evaluerbar deltager anses for at være TE ADA+, hvis forsøgspersonen har mindst én post-baseline-titer, der er en 4-fold eller større stigning i titer fra baseline-måling.
Hvis baseline-resultatet er ADA ikke til stede, er deltageren TE ADA+, hvis der er mindst ét post-baseline-resultat af ADA til stede med titer >= 1:20.
|
Måned 1 til og med måned 6
|
Farmakokinetik (PK): Serumkoncentrationer af Galcanezumab
Tidsramme: Måned 6
|
Farmakokinetik (PK): Serumkoncentrationer af Galcanezumab.
|
Måned 6
|
Plasmakoncentration af calcitonin-gen-relateret peptid (CGRP)
Tidsramme: Måned 6
|
Plasmakoncentration af calcitonin-gen-relateret peptid (CGRP).
|
Måned 6
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Stauffer VL, Turner I, Kemmer P, Kielbasa W, Day K, Port M, Quinlan T, Camporeale A. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. J Headache Pain. 2020 Jun 23;21(1):79. doi: 10.1186/s10194-020-01148-9.
- Bangs ME, Kudrow D, Wang S, Oakes TM, Terwindt GM, Magis D, Yunes-Medina L, Stauffer VL. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020 Jan 17;20(1):25. doi: 10.1186/s12883-020-1609-7. Erratum In: BMC Neurol. 2020 Mar 13;20(1):90.
- Kielbasa W, Quinlan T. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine. J Clin Pharmacol. 2020 Feb;60(2):229-239. doi: 10.1002/jcph.1511. Epub 2019 Sep 4.
- Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM. Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache. 2022 Feb;62(2):198-207. doi: 10.1111/head.14257. Epub 2022 Jan 25.
- Citrome L, Sanchez Del Rio M, Dong Y, Nichols RM, Tockhorn-Heidenreich A, Foster SA, Stauffer VL. Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm. Adv Ther. 2021 Aug;38(8):4442-4460. doi: 10.1007/s12325-021-01848-x. Epub 2021 Jul 15.
- Jedynak J, Eross E, Gendolla A, Rettiganti M, Stauffer VL. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials. J Headache Pain. 2021 May 28;22(1):48. doi: 10.1186/s10194-021-01222-w.
- Pozo-Rosich P, Samaan KH, Schwedt TJ, Nicholson RA, Rettiganti M, Pearlman EM. Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis. Adv Ther. 2021 Jun;38(6):3154-3165. doi: 10.1007/s12325-021-01708-8. Epub 2021 May 5.
- Ament M, Day K, Stauffer VL, Skljarevski V, Rettiganti M, Pearlman E, Aurora SK. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain. 2021 Feb 6;22(1):6. doi: 10.1186/s10194-021-01215-9. Erratum In: J Headache Pain. 2021 Aug 26;22(1):100.
- Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL. Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials. Adv Ther. 2021 Mar;38(3):1614-1626. doi: 10.1007/s12325-021-01632-x. Epub 2021 Feb 5. Review.
- Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia. 2021 Mar;41(3):340-352. doi: 10.1177/0333102420966658. Epub 2020 Nov 3.
- Ailani J, Andrews JS, Rettiganti M, Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. 2020 Oct 17;21(1):123. doi: 10.1186/s10194-020-01190-7.
- Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x. Erratum In: J Headache Pain. 2019 Dec 27;20(1):118.
- Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials. Headache. 2019 Jun;59(6):834-847. doi: 10.1111/head.13508. Epub 2019 Apr 3.
- Forderreuther S, Zhang Q, Stauffer VL, Aurora SK, Lainez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018 Dec 29;19(1):121. doi: 10.1186/s10194-018-0951-2.
- Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK. Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies. Headache. 2019 Feb;59(2):192-204. doi: 10.1111/head.13443. Epub 2018 Nov 21.
- Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 15768
- I5Q-MC-CGAH (Anden identifikator: Eli Lilly and Company)
- 2015-001882-17 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- Studieprotokol
- Statistisk analyseplan (SAP)
- Klinisk undersøgelsesrapport (CSR)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AfsluttetSund og rask | Kropssammensætning